Shionogi & Co., Ltd.

Shionogi & Co., Ltd.

10.01
USD
+0.15
(+1.47%)
0.96EPS
8.96P/E
14.51BMarket Cap
Feb 05Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
144.46
137.76
158.98
175.32
181.18
196.38
180.27
161.93
185.63
239.33
250.42
258.1
294.17
331.08
Basic EPS, GAAP
20.25
22.15
34.2
43.39
57.23
73.22
66.08
60.95
63.24
103.75
93.26
100.37
120.78
154.9
Free Cash Flow per Basic Share
30.96
16.2
44.72
45.86
59.28
74.51
64.98
41.46
39.05
78.91
72.53
84.42
107.3
- -
Dividend per Share
7.34
8.08
9.34
11.44
12.74
14.75
16.83
17.73
18.36
20.27
25.25
28.68
33.07
19.08
Book Value per Share
231.39
243.38
261.46
273.81
388.06
433.85
420.59
468.67
540.39
624.14
727.63
802
992.05
1,043.28
Tangible Book Value per Share
195.08
202.18
224.73
226.08
359.79
406.4
387.85
421.08
490.07
563.93
649.35
708.14
869.24
674.62
Basic Weighted Avg Shares
2,006
1,989
1,950
1,933
1,902
1,874
1,849
1,835
1,805
1,783
1,737
1,698
1,699
1,701
Sales/Revenue/Turnover
289,717
273,991
309,973
338,890
344,667
367,960
333,371
297,177
335,138
426,684
435,081
438,268
499,677
563,206
Operating Margin (%)
21.36
18.38
29.49
31.92
33.43
39.43
39.18
39.52
32.92
34.92
35.24
35.73
33.37
35.25
Depreciation Expense
15,625
15,650
15,868
16,340
19,007
14,431
14,115
14,779
16,351
17,165
18,323
20,933
26,968
31,166
Net Income, GAAP
40,618
44,060
66,687
83,879
108,866
137,191
122,193
111,858
114,185
184,965
162,030
170,435
205,159
263,500
Effective Tax Rate (%)
35.56
46.11
31.63
31.85
20.81
21.33
22.91
21.64
10.16
16.26
19.02
15.55
13.81
0.77
Profit Margin (%)
14.02
16.08
21.51
24.75
31.59
37.28
36.65
37.64
34.07
43.35
37.24
38.89
41.06
46.79
Working Capital
169,885
192,154
243,629
252,789
330,782
397,496
434,907
456,058
534,809
625,640
650,298
729,112
482,905
112,218
LT Debt
10,034
30,094
30,074
30,054
24,124
6,006
4,791
4,608
3,729
6,397
8,753
18,418
18,895
18,291
Total Equity
467,833
478,882
513,876
526,210
734,814
813,087
765,203
864,550
993,285
1,121,878
1,252,561
1,362,496
1,686,204
1,772,763
Return on Invested Capital (%)
7.94
5.24
11.47
12.83
13.27
13.86
12.19
10.85
10.33
11.39
10.1
9.83
7.57
10.15
Return on Capital (%)
8.3
8.75
12.7
15.32
16.48
17.57
15.56
13.66
12.36
17.76
14.1
13.51
11.28
14.22
Return on Common Equity (%)
9.19
9.39
13.55
16.25
17.37
17.82
15.53
13.88
12.54
17.82
13.88
13.12
13.47
16.73

Capital Structure

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
4,900
665,499
665,840
LT Borrowings
- -
- -
- -
LT Finance Leases
17,900
18,895
18,291
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,699
1,699
1,699
Market Capitalization
2,389,555
2,989,430
2,358,381

Working Capital

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
914,700
1,310,335
926,651
Cash, Cash Equivalents & STI
592,900
1,022,145
614,751
Accounts Receivable, Net
193,000
159,773
173,180
Inventories
98,900
99,396
108,961
Total Current Liabilities
156,600
827,430
814,433
Payables & Accruals
- -
- -
- -
ST Debt
4,900
665,499
665,840
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.18%
14.41%
23.76%
Free Cash Flow
12.47%
24.53%
27.14%
Net Income, GAAP
13.94%
15.45%
20.37%
Sales/Revenue/Turnover
5.43%
11.36%
14.01%
Total Cash Common Dividend
12.08%
11.74%
15.35%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
97,586
116,384
119,630
104,668
438,268
2026
99,781
113,184
147,735
138,977
499,677
2027
163,310
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
18.05
30.86
29.78
21.53
100.37
2026
23.17
25.96
43.87
27.59
120.78
2027
57.51
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
14.12
0.22
14.18
0.14
28.68
2026
16.55
-0.01
- -
- -
33.07
2027
19.11
- -
- -
- -
- -

Company Description

CEO
Isao Teshirogi
Full Time Employees
6,223
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Park Tower Osaka OS Japan 530-0011
IPO Date
May 16, 1949
Business
Shionogi & Co., Ltd. is a research-driven Japanese pharmaceutical company dedicated to the discovery, development, production, and worldwide distribution of innovative medicines, diagnostic solutions, and medical devices. The company cultivates a strong global presence, with operations spanning Japan, North America, and Europe. The firm's portfolio features key treatments such as Fetroja (cefiderocol) for managing multidrug-resistant Gram-negative bacterial infections and Xofluza, an antiviral medication for influenza, which recently saw a new granule formulation launch. Additionally, Shionogi holds a significant equity stake in ViiV Healthcare, contributing to vital therapies for HIV, including the development of integrase inhibitors. Other marketed products include Symproic (naldemedine tosilate) for opioid-induced constipation. Shionogi maintains a robust development pipeline, primarily concentrated on areas of high unmet medical need like infectious diseases, central nervous system disorders, and pain. Promising candidates in clinical stages include a COVID-19 preventive vaccine (Covgoze), an oral antiviral treatment for COVID-19 (Ensitrelvir Fumaric Acid, also known as Xocova in Japan), and an investigational long-acting formulation for COVID-19 pre-exposure prophylaxis. The company is also advancing Zuranolone for depression, in collaboration with Sage Therapeutics, with a new drug application submitted in Japan. In the realm of quality of life diseases, the digital therapeutic app ENDEAVORRIDE® (SDT-001) for pediatric Attention-Deficit/Hyperactivity Disorder received domestic marketing approval in Japan. Other pipeline projects target conditions such as Fragile X syndrome and Alzheimer's disease (BPN14770), decompensated liver cirrhosis (ADR-001), acute ischemic stroke (Redasemtide Trifluoroacetate), and various solid tumors (S-531011). The pipeline further includes novel antibiotics like S-743229 for complicated urinary tract infections and S-649228 for Gram-negative infections, stemming from the acquisition of Qpex Biopharma, Inc. Recent strategic initiatives include the acquisition of Torii Pharmaceutical and Akros Pharma in May 2025 to bolster domestic commercial reach and enhance global development capabilities, particularly in areas like dermatology and pediatrics. Furthermore, Shionogi announced a planned merger with its wholly-owned subsidiary, Shionogi Pharma Co., Ltd., set for April 2027, to fortify its production and supply chain resilience. Established in 1878, Shionogi & Co., Ltd. is headquartered in Osaka, Japan.

Company News

  • SGIOY or UTHR: Which Is the Better Value Stock Right Now?

  • Not IonQ. Not Rigetti. This Quantum Computing Stock Could Be the Next to Soar.

  • SGIOY vs. UTHR: Which Stock Is the Better Value Option?

  • Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Stock Jumps 6.2% on Analyst Upgrade

  • Shionogi & Co. (SGIOY) Upgraded to Buy: Here's What You Should Know

  • SGIOY or UTHR: Which Is the Better Value Stock Right Now?

  • Financial Analysis: Orion OYJ (OTCMKTS:ORINY) versus Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)

  • Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Here’s What Happened

  • Shionogi & Co., Ltd. (OTCMKTS:SGIOF) Shares Down 7.1% – Here’s What Happened

  • Shionogi to Showcase Advancements Across its Infectious Disease Portfolio at IDWeek 2026

  • Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats

  • Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Beats Q1 Earnings Estimates

  • Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth

  • New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure

  • Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats

  • Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)

  • SGIOY vs. SDZNY: Which Stock Is the Better Value Option?

  • Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease

  • SGIOY vs. SDZNY: Which Stock Should Value Investors Buy Now?

  • SGIOY or SDZNY: Which Is the Better Value Stock Right Now?